GU prostate

Date 01 October 2019
Event ESMO 2019 Congress
Session Congress Highlights 1 - The best of ESMO 2019
Topics Prostate Cancer
Presenter Joaquin Mateo
Authors J. Mateo
  • Vall d'Hebron University Hospital, 08035 - Barcelona/ES

LBA12_PR: PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations by David Olmos